SCHEMBL15212090

SCHEMBL15212090

COc1ccc(-c2cncc(NS(=O)(=O)c3cc(Cl)ccc3OC(F)(F)F)c2)cc1

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALPL P05186 20/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15212174 0.93 ALPL (0.69) ALPL
SCHEMBL15212425 0.90 ALPL (0.72) ALPL
SCHEMBL15212277 0.90 ALPL (1.00) ALPL
SCHEMBL15220368 0.89 ALPL (0.69) ALPL
SCHEMBL15220378 0.89 ALPL (0.67) ALPL
SCHEMBL15212026 0.87 ALPL (0.82) ALPL
SCHEMBL15212152 0.84 ALPL (1.00) ALPL
SCHEMBL15212328 0.84 ALPL (0.82) ALPL
SCHEMBL15211902 0.83 ALPL (0.88) ALPL
SCHEMBL15211844 0.83 ALPL (0.87) ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) 2019-08-06 US disclosed
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) 2019-08-06 US disclosed
US-20190010126-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford Burnham Prebys Medical Discovery Institute 2019-01-10 US disclosed
US-9884826-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-02-06 US disclosed
US-9884826-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-02-06 US disclosed
US-20160355479-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2016-12-08 US disclosed
US-20160355479-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2016-12-08 US disclosed
US-9458147-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2016-10-04 US disclosed
US-9458147-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2016-10-04 US disclosed
US-20150011551-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford- Burnham Medical Reseach Institute (US) 2015-01-08 US disclosed
EP-2817292-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford-Burnham Medical Research Institute (US) 2014-12-31 EP disclosed
WO-2013126608-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-08-29 WO disclosed
WO-2013126608-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors TNNI3, TNKS1BP1, TNNT2 ALPL 503/4885
US-20150011551-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 ALPL 503/4885
US-20190010126-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 ALPL 503/4885
US-20160355479-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 ALPL 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.